Loading...


Prostate Cancer Library
Degarelix is the new injectable treatment

-

Degarelix Approved for Advanced Prostate Cancer

Votes:10 Comments:0
MONDAY, Dec. 29 (HealthDay News) -- The injected drug degarelix has been approved by the U.S. Food and Drug Administration to treat advanced prostate cancer. It belongs to a class of drugs called READ MORE
http://news.yahoo.com/s/hsn/20081229/hl_hsn/degarelixapprovedforadvanc...
Degarelix is the new injectable treatment for patients with advanced prostate cancer, a killer of 28,000 men last year. Developed by Ferring Pharmaceuticals, degarelix blocks the hormone testosterone that feeds prostate cancer cells. The number-one priority for prostate cancer patients is to stop the body's testosterone production because the hormone helps the cancer grow. Testosterone is like a running back and degarelix is the defensive line. It shuts testosterone production down—hard and fast. This treatment stimulates an extremely large amount of testosterone production in a few days—an overproduction that causes the body to automatically stop generating testosterone. A major concern with this treatment (called luteinizing hormone releasing hormone agonist) is that some patients with advanced prostate cancer might not survive the initial hormone surge.
Alternative Remedies Library , New Jersey Assisted Living Library
-
Search
Search
Search
Search
Login
StudySphere
Privacy Policy